Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Deep brain stimulation (DBS) reduces the motor symptoms of Parkinson's disease. The two most common targets are the subthalamic nucleus and the globus pallidus. Dual target deep brain stimulation may better reduce symptoms and minimize side effects, but the optimal parameters of dual target deep brain stimulation and their potential interactions are unknown.
Objective: Our purpose was to quantify the frequency response of dual target DBS on bradykinesia and beta oscillations in participants with Parkinson's disease, and to explore intrahemispheric pulse delays as a means to reduce total energy delivered.
Methods: We applied dual target DBS using the Summit RC+S in six participants, varying deep brain stimulation frequency.
Results: Dual target DBS at 50 Hz was effective at reducing bradykinesia, whereas increasing deep brain stimulation frequency up to 125 Hz also significantly reduced beta power. This frequency effect on beta power was replicated in a biophysical model. The model suggested that 22 Hz dual target deep brain stimulation, with an intrahemispheric delay of 40 ms, can reduce beta power by 87%.
Conclusion: We conclude that dual target DBS at 125 Hz best reduced bradykinesia. However, low frequency DBS with an appropriate intrahemispheric delay could improve symptom relief.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974944 | PMC |
| http://dx.doi.org/10.1101/2025.03.25.25324612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Risk factors for coronary in-stent restenosis in Moroccan patients: a retrospective case-control study.
Cell Mol Biol (Noisy-le-grand)
September 2025
Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.
View Article and Find Full Text PDFSystematic engineering of TROP2-targeted CAR T-cell therapy overcomes resistance pathways in solid tumors.
Cancer Immunol Res
September 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields responses in TROP2+ solid tumors but lacks the durability observed with other immunotherapy-based approaches, we developed novel TROP2-targeting chimeric antigen receptor (CAR) T cells as an alternative.
View Article and Find Full Text PDFProphage-encoded virulence factor, Gp05, contributes to endothelial cell dysfunction and immune evasion to promote persistent methicillin-resistant endovascular infections.
mBio
September 2025
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Unlabelled: Methicillin-resistant (MRSA) is a leading cause of endovascular infections, where interactions with endothelial cells play a critical role in pathogenesis. Gp05, a prophage-encoded protein, has previously been implicated in promoting antibiotic persistence by modulating MRSA cellular physiology and evading neutrophil-mediated killing. In this study, we investigated the role of Gp05 in MRSA-endothelial cell interactions, focusing on its impact on bacterial adhesion, invasion, cytotoxicity, and the host inflammatory response.
View Article and Find Full Text PDFFlexible, Transparent, and Microfluidic-Compatible Wafer-Scale Metamaterial Sheets for Dual SEF and SERS Sensing.
ACS Appl Mater Interfaces
September 2025
National Key Laboratory of Advanced Micro and Nano Manufacture Technology, Shanghai Jiao Tong University, Shanghai 200240, China.
Integrating surface-enhanced fluorescence (SEF) and surface-enhanced Raman spectroscopy (SERS) into a single probe is a natural step forward for plasmon-enhanced spectroscopy (PES), as SEF enables enhanced fluorescent imaging for fast screening of targets, while SERS allows ultrasensitive trace molecular characterization with specificity. However, many challenges remain, e.g.
View Article and Find Full Text PDF